[Skip to Navigation]
Invited Commentary
January 2, 2020

Importance of Partial Losses of Chromosome 3 in Uveal Melanoma in the BAP1 Gene Region

Author Affiliations
  • 1Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
  • 2Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Liverpool, United Kingdom
JAMA Ophthalmol. 2020;138(2):188-189. doi:10.1001/jamaophthalmol.2019.5491

Close to 30 years ago, 3 research groups independently described chromosomal abnormalities in primary uveal melanoma, with all 3 highlighting the presence of monosomy 3 in some of the examined cases. All groups proposed that monosomy 3 may play an important role in uveal melanoma progression. This theory was later confirmed by Prescher and colleagues,1 who examined the outcome of 54 patients with primary uveal melanoma, 30 (55%) of whom had monosomy 3 tumors, with 17 of these 30 patients (57%) dying of the disease within 3 years. In the meantime, numerous research groups have confirmed the significance of monosomy 3 loss in primary uveal melanoma. Damato et al2 used cytogenetic testing of consented patients with primary uveal melanoma to stratify these patients into risk groups with respect to metastasis development and to assess liver surveillance management. In the meantime, molecular genetic testing has been incorporated into algorithms that integrate other known strong prognostic factors to refine metastatic risk.3 During the past decade, understanding of the underlying mutations present in primary uveal melanoma and how these may be associated with the described chromosomal alterations has advanced significantly.4 Of particular importance is the gene BAP1 (3p21.31-p21.2) and its temporal and functional association with the loss of 1 copy of chromosome 3.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words